KarXT, a proprietary oral modulator of muscarinic
receptors, is the Company's lead product candidate that combines xanomeline, a novel muscarinic
agonist, with trospium, an approved muscarinic
antagonist, to preferentially stimulate muscarinic
receptors in the central nervous system (CNS).
That approach came as news to many meeting attendees, based on results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations who was taking only a long-acting muscarinic
That approach came as news to many internists, at least going by results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations despite having used a long-acting muscarinic
Karuna Pharmaceuticals, a clinical-stage pharmaceutical company, targets muscarinic
cholinergic receptors for the treatment of Central Nervous System disorders.
The products are a muscarinic
antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Ultibro Breezhaler is an inhaled once-daily fixed-dose combination of indacaterol (a long-acting beta 2 agonist; LABA) and glycopyrronium bromide (a long-acting muscarinic
antagonist; LAMA) and Seebri Breezhaler is an inhaled fixed-dose formulation of glycopyrronium bromide (a long-acting muscarinic
Subtypes, regional distribution and synaptic localization of muscarinic
The expanded indication for the once-daily single inhaler triple therapy would enable use by patients not adequately treated by a long-acting muscarinic
receptor antagonist and long-acting beta2-agonist.
antagonists (LAMAs) is a selective M3-receptor antagonist with obvious efficiency and fewer adverse reactions.
This overstimulation of acetylcholine receptors is followed by paralysis of cholinergic synaptic transmission in the central nervous system, in autonomic ganglia at parasympathetic and some sympathetic nerve endings and in somatic nerves.7-9 The mainfestations of OPP may be classified into effects secondary to nicotinic, muscarinic
and CNS receptor overstimulation.
While comparing the effect of cholinergic blocker, atropine (a muscarinic
blocker) on acetylcholine-induced contractility between non-Hirschsprung and Hirschsprung's cases, it was observed that gut contractility induced by acetylcholine was blocked significantly in non-Hirschsprung's cases whereas in Hirschsprung's cases atropine failed to block the responses.